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Background: Angiotensin-converting enzyme inhibitors (ACEIs) are largely employed for treating patients with
left ventricular dysfunction (LVD), but their efﬁcacy may be negatively affected by concomitant administration
of acetylsalicylic acid (ASA), with some difference among the different compounds.
Hypothesis: The interaction between ASA and the two ACEIs zofenopril and ramipril may result in a different
impact on survival of cardiac patients, due to differences in the pharmacological properties of the two ACEIs.
Methods: This phase IIIb, randomized, double-blind, parallel-group,multicenter, European study compared the
safety and efﬁcacy of zofenopril (60 mg/day) and ramipril (10 mg/day) plus ASA (100 mg/day), in 771 patients
with LVD (clinical signs of heart failure or a left ventricular ejection fraction<45%) following acute myocardial
infarction (AMI). The primary study end point was 1-year combined occurrence of death or hospitalization for
cardiovascular causes.
Results: In the intention-to-treat population, the primary outcome was signiﬁcantly reduced by zofenopril (n
= 365) vs ramipril (n = 351) (odds ratio [OR]: 0.70, and 95% conﬁdence interval [CI]: 0.51-0.96; P = 0.028)
as a result of a decrease in cardiovascular hospitalization (OR: 0.64,95% CI: 0.46-0.88; P = 0.006). Mortality
rate was not signiﬁcantly different between the 2 treatments (OR: 1.51, 95% CI: 0.70-3.27; P = 0.293).
Blood pressure values did not signiﬁcantly change during the 1-year follow-up. N-terminal pro-brain natriuretic
peptide levels were progressively reduced during the study, with no statistically signiﬁcant between-treatment
differences. Proportion of patients with deterioration of renal function during the study was similar between
the 2 groups. Drug safety proﬁle was comparable between treatments.
Conclusions: In patients with LVD following AMI, the efﬁcacy of zofenopril associated with ASA was superior to
that of ramipril plus ASA, indicating some important clinical implications for the future use of ACEIs in patients
with LVD or overt heart failure.
Trial registration: EudraCT Number: 2004-001150-88 (www.
clinicaltrialsregister.eu); Italian Ministry of Health Code: GUID
OTT_III_2004_001 (https://oss-sper-clin.agenziafarmaco.it).
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Introduction
A combination of an angiotensin-converting enzyme
inhibitor (ACEI) and acetyl salicylic acid (ASA) is a
widely used treatment in patients with both heart failure
and ischemic heart disease.1 However, the safety of such
an association has been questioned because both drugs
interfere with a prostaglandin-mediated pathway.2 To date
there is conflicting evidence on the possible negative
interaction between ASA and ACEIs on survival of cardiac
patients.1,3–6 Some meta-analyses seem to suggest an
antagonistic interaction between the 2 drugs, with reduced
efficacy of ACEIs on morbidity and mortality.7,8
The differences in the results of the studies investigating
the effects of the combination of ACEI plus ASA are basically
post hoc or retrospective, with some differences in study
design, choice of the evaluation parameter, patient charac-
teristics and inclusion criteria, and type and the dosage of
each selected treatment.2 In addition, some differences in
the pharmacological profile of ACEIs can affect the extent
of interaction with ASA.9–12 Given the controversy, cur-
rent guidelines suggest that further prospective studies are
required in this field.13,14
The objective of this prospective, double-blind, random-
ized, parallel group study was to investigate the efficacy
and safety of early administration of the ACEIs zofenopril
and ramipril plus ASA in patients with acute myocardial
infarction (AMI) complicated by left ventricular systolic
dysfunction (LVD).
Methods
Study Population
Male and non-pregnant female patients aged 18 to 85 years
with a confirmed diagnosis of ST-elevation myocardial
infarction (STEMI) or non–ST-elevation myocardial infarc-
tion (NSTEMI) in the 24 hours preceding the enrollment
(not treated with primary percutaneous transluminal angio-
plasty [PTCA], treated or not with thrombolysis, and recom-
mended pharmacologic treatment) and with clinical and/or
echocardiographic evidence of LVD (Killip class >1, plus
3rd heart sound or pulmonary congestion on chest x-ray,
and/or a left ventricular ejection fraction [LVEF] <45%)
were enrolled in this study. The protocol was amended
to also allow inclusion of patients treated with PTCA or a
coronary artery bypass graft, representing the majority of
eligible patients.
The main exclusion criteria were: severe hypotension
(systolic blood pressure [SBP] <90 mm Hg), history of
renal artery stenosis, significant valvular disease, cur-
rent treatment with ACEIs, angiotensin-receptor blockers
(ARBs) or ASA, hypersensitivity to these drugs, history of
stroke (previous 3 months), renal failure (serum creatinine
>2.5 mg/dL), severe liver impairment (serum transami-
nases 3 times the upper normal limit), hematologic diseases,
or other significant clinical conditions. Anticoagulant treat-
ment was allowed only during the acute phase of the
infarction.
Study Design
This was a phase IIIb randomized, double-blind, parallel-
group study, involving patients with acute myocardial
infarction (MI) and LVD. The study was conducted at 79
Hospitals in 8 different European countries and coordinated
by the Internal Medicine Unit of the University of Bologna
(Italy). The study was performed following the Guidelines
for Good Clinical Practice and the Declaration of Helsinki.
The protocol was reviewed and approved by the ethics
committee of each participating center. Written informed
consent was obtained from each patient before enrollment.
Study Protocol
Eligible patients entered a 4-day open-label phase when
zofenopril was administered to all patients according to
an up-titration scheme. This choice was based on ethical
and regulatory reasons, based on previous evidence of
efficacy and safety of the early zofenopril treatment in
patients with anterior AMI.15 On days 1 and 2, patients
received 7.5 mg zofenopril twice daily plus an evening dose
of 100 mg ASA. On days 3 and 4 the zofenopril dose was
doubled (15 mg twice daily), whereas the dose of ASA
remained unchanged. On day 5 patients were randomized
1:1 double-blind (using a centralized, computer-generated,
randomization list) to receive 30 mg zofenopril twice daily
plus 100 mg ASA once daily, or 5 mg ramipril twice daily
plus 100 mg ASA once daily for 12 months. Originally the
study design foresaw 4 treatment arms with 2 different
doses of ASA (100 and 325 mg once daily). Because patients
submitted to primary PTCA were treated with clopidogrel,
which cannot be combined with high-dose aspirin according
to recent studies and recommendations,16,17 the protocol
was amended, deleting from the study design the 325 mg
ASA arm. The amendment was submitted to and approved
by ethics committees in April 2005 (no patient enrolled
before the amendment received 325 mg ASA).
The first patient was enrolled in March 2005, and the last
patient was completed in July 2009. Zofenopril and ramipril
were supplied as identical oral tablets (overencapsulation
technique). In the event of severe hypotension (SBP
<90 mm Hg) or any other clinically relevant adverse event,
treatment was discontinued, and the patient was withdrawn
from the study. The study medications were administered
in combination with standard recommended treatments for
AMI, excluding other ACEIs, ARBs, and antiplatelet drugs
other than ASA, clopidogrel, or ticlopidine. Concomitant
chronic anticoagulant treatment was allowed in the acute
phase of MI, and in case of a specific indication or in
patients who reached a study end point. Patients were seen
at enrollment (visit 1), at randomization (visit 2, 5 days
after enrolment), and after 1, 6, and 12 months (visits 3,
4, and 5). Blood pressure and heart rate were measured
on each visit before the morning drug dose or in case
of suspected hypotension. A physical examination, a 12-
lead electrocardiogram, and laboratory tests (hematology,
clinical chemistry, and urinalysis) were performed at visit
1. These tests were repeated at visit 2 and at study end. An
echocardiogram was performed, blood samples were drawn
(centralized estimation of N-terminal pro-brain natriuretic
peptide [NT-proBNP]), and occurrence of concomitant
diseases, adverse events, use of concomitant medications,
and compliance to study drugs were checked at each study
visit.
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Statistical Analysis
The primary study end point was the comparison
between zofenopril- and ramipril-treated patients at the 1-
year combined occurrence of cardiovascular mortality or
hospitalization for cardiovascular causes (congestive heart
failure, AMI, angina, or a decline in LVEF>15%). Secondary
study end points were hospitalization for cardiovascular
causes, changes in LVEF, left ventricular end-diastolic and
end-systolic volumes, plasma NT-proBNP levels and blood
pressure, overall incidence of noncardiovascular adverse
events, severe hypotension, and deterioration of renal
function (decline >15% of glomerular filtration rate or
glomerular filtration rate [GFR], Cockroft-Gault formula).
The primary and secondary end points were confirmed
by an independent end point and safety committee that
directly reviewed patients’ records in a blinded fashion.
Data management and statistical analysis were carried
out by a team under the supervision of the study
coordinators.
The study was planned to enroll 896 patients (448
per treatment group), with an expected 1-year event
rate of 15% under zofenopril and 25% under ramipril.
The sample size estimation was based on a 2-sided χ2
test, with a 90% power and a 5% significance level. A
25% drop-out rate was taken into account to obtain at
least 672 evaluable patients (336 per treatment group).
Event rates for sample size estimation were assumed
from the Survival of Myocardial Infarction Long-term
Evaluation group-1 study (SMILE-1) for zofenopril (10%
rate of major cardiovascular events after 6 weeks in
772 patients)15 and from the Acute Infarction Ramipril
Efficacy study (AIRE) for ramipril (28% of patients with
any event in 1.104 patients, of whom 86% treated with 5 mg
twice-daily).18
Evaluation of the efficacy end points was carried out in the
intention-to-treat population (patients treated with at least
1 dose of study medication and documenting at least once
the measure of the primary efficacy assessment, even in
case of protocol violation or premature withdrawal from the
study).
The baseline characteristics and the distribution of
variables in the zofenopril and ramipril populations were
compared using a χ2 test for categorical variables and
Student t test for continuous variables. A logistic regression
model was used to assess the difference between treatment
groups with respect to cardiovascular mortality and
morbidity rate, calculating the estimated odds ratio (OR)
and the corresponding 95% confidence interval (CI). To
account for possible confounding factors, the analysis
was also adjusted for age, gender, GFR, LVEF, Killip
class, revascularization, diabetes, metabolic syndrome,
hypercholesterolemia, low high-density lipoprotein HDL,
STEMI vs NSTEMI, NT-proBNP, and heart rate. The χ2
analysis was applied to data with the Mantel-Haenszel
extension for the comparison between the 2 treatment
groups. Time-to-event curves were also drawn using Kaplan-
Meier estimates, and the survival analysis was performed
according to the log-rank statistics.
All P values are 2-tailed and the minimum level of
statistical significance was set at P < 0.05.
Results
Patient Population
Overall, 871 patients were enrolled into the study, and
771 were randomized to treatment (389 patients to
zofenopril and 382 patients to ramipril) (Figure 1). Of the
randomized patients, 64 (17%) receiving zofenopril and
58 (15%) receiving ramipril were prematurely withdrawn
from the study (a drop-out frequency lower than the
25% planned). The number of patients included in the
intention-to-treat population was 716 (365 treated with 60
mg zofenopril and 351 with 10 mg ramipril). Treatment
compliance (subjects taking ≥75% of drug dose) was
high and comparable between groups (zofenopril 96%,
ramipril 96%, ASA zofenopril group 97%, ASA ramipril group
96%).
At baseline there were no significant differences in
demographic and clinical characteristics between the
treatment groups, except for the proportion of patients with
hypertension (P = 0.033), previous PTCA (P = 0.044) and
LVEF <40% (p = 0.009) (table 1).
Primary Outcome Measure
During the 12 months of double-blind randomized treat-
ment, cardiovascular death or hospitalization occurred in
128/351 patients in the ramipril (37%) and in 105/365
patients in the zofenopril group (29%) (Figure 2A). Treat-
ment with zofenopril was associated with a 30% significantly
(P = 0.028) lower risk of achieving the combined end
point (OR: 0.70, 95% CI: 0.51-0.96). Risk estimate did
not differ after adjustment for confounding factors (OR:
0.68, 95% CI: 0.49-0.95); [P = 0.024]. The distribution of
fatal and nonfatal cardiovascular events is reported in
Table 2.
Figure 1. Flow diagram of the patients throughout the study. Analyzed
patients refer to those treated with at least 1 dose of study medication
and who had documented at least once the measure of the primary
efﬁcacy assessment, even in case of protocol violation (intention-to-treat
population).
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Table 1. Baseline Demographic Characteristics of the Intention-to-Treat
Population (N = 716)
Characteristics Zofenopril (n = 365) Ramipril (n = 351)
Age, mean ± SD, y 61 ± 11 61 ± 11
Gender, n (%)
Male 268 (73) 276 (79)
Female 97 (27) 75 (21)
BMI, mean ± SD, kg/m2 28 ± 4 28 ± 4
Diabetes, n (%) 68 (19) 63 (18)
Treated
hypercholesterolemia, n
(%)
68 (19) 72 (21)
Treated hypertension, n
(%)
237 (65) 200 (57)
Relevant concomitant treatments, n (%)
ACE-inhibitors 13(4) 3 (1)
Angiotensin II
antagonists
4 (1) 1 (1)
β-blockers 199 (55) 177 (50)
α-blockers 24 (7) 28 (8)
Calcium antagonists 8 (2) 13 (4)
Diuretics 73 (20) 74 (21)
Digoxin — 3 (1)
Nitrates 128 (35) 117 (33)
Antiarrhythmic drugs 14 (4) 9 (3)
Statins 217 (59) 200 (57)
Other lipid lowering
drugs
15 (4) 17 (5)
Other cardiovascular
drugs
47 (13) 32 (9)
Atrial ﬁbrillation, n (%) 7 (2) 2 (1)
Peripheral arterial
occlusive disease, n (%)
17 (5) 18 (5)
Previous myocardial
infarction, n (%)
72 (20) 61 (18)
Angina pectoris, n (%) 140 (39) 123 (35)
Prior PTCA, n (%) 26 (7) 13 (4)
Prior CABG, n (%) 6 (2) 6 (2)
Congestive heart failure, n
(%)
24 (7) 25 (7)
Killip class on admission, n (%)
I 116 (31) 120 (34)
II-IV 249 (69) 231 (66)
Table 1. Continued
Characteristics Zofenopril (n = 365) Ramipril (n = 351)
Infarct location (%)
Anterior 198 (54) 185 (53)
Posterior 33 (9) 21 (6)
Lateral 26 (7) 26 (7)
Inferoposterior 67 (18) 70 (20)
Other 40 (11) 49 (14)
PTCA performed at entry, n
(%)
115 (32) 109 (31)
Thrombolytic therapy
performed at entry, n
(%)
141 (39) 134 (38)
Type of thrombolytic therapy, n (%)
Streptokinase 56 (15) 60 (17)
Alteplase 22 (6) 18 (5)
Tenecteplase 42 (12) 36 (10)
Reteplase 9 (2) 6 (2)
Other 12 (3) 14 (4)
Estimated GFR, mean ±
SD, mL/min
85 ± 32 89 ± 34
NT-proBNP, median (25th
and 95th percentile),
pg/mL
1118 (448–2514) 1114 (521–2342)
LVEF mean ± SD, % 42 ± 8 43 ± 7
LVEF ≤40%, n (%) 151 (41) 111 (32)
SBP, mean ± SD, mm Hg 139 ± 24 140 ± 24
DBP, mean ± SD, mm Hg 83 ± 14 83 ± 13
HR, mean ± SD, mm Hg 81 ± 17 79 ± 16
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass
index; CABG, coronary artery bypass graft; DBP, diastolic blood
pressure; GFR, glomerular ﬁltration rate (estimated by Cockroft-Gault
formula); HR, heart rate; LVEF, left ventricular ejection fraction; NT-
proBNP, N-terminal pro-brain natriuretic peptide; PTCA, percutaneous
transluminal coronary angioplasty; SBP, systolic blood pressure; SD,
standard deviation.
Secondary Outcome Measures
The rate of hospital admission for cardiovascular causes was
significantly reduced by 35% in patients receiving zofenopril
(88/365, 24%) as compared to those receiving ramipril
(117/351, 33%) (OR: 0.64, 95% CI: 0.46-0.88, P = 0.006)
(Figure 2B). The OR for 1-year risk of cardiovascular
hospitalization was 0.65 (95% CI: 0.46-0.91) (P = 0.012) after
adjustment for covariates.
Cumulative incidence of cardiovascular death in the
course of the 1 year of follow-up was not significantly
different between ramipril (11 deaths, 3% of patients)
and zofenopril (17 deaths, 5% of patients) (OR: 1.51, 95%
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Table 2. Absolute and Relative Frequency (%) of Causes of Cardiovascular
Death and of Major Cardiovascular Events Requiring Hospitalization in the
Intention-to-Treat Population (N = 716)
Zofenopril (n = 365),
N (%)
Ramipril (n = 351),
N (%)
Cardiovascular death
Congestive heart failure 4 (1.1) 2 (0.6)
Acute myocardial
infarction
6 (1.6) 1 (0.3)
Sudden death 6 (1.6) 6 (1.7)
Cardiac rupture 1 (0.3) 1 (0.3)
Stroke — 1 (0.3)
All causes of
cardiovascular death
17 (4.7) 11 (3.1)
Major cardiovascular events requiring hospitalization
Congestive heart failure 4 (1.1) 7 (2.0)
Acute myocardial
infarction
13 (3.6) 16 (4.6)
Angina pectoris 20 (5.5) 22 (6.3)
Decline in left
ventricular ejection
fraction >15%
15 (4.1) 28 (8.0)
Revascularization 25 (6.8) 32 (9.1)
Other causes 11 (3.0) 12 (3.4)
All causes of major
cardiovascular events
88 (24.1) 117 (33.3)
CI: 0.70-3.27; P = 0.293). Adjusted risk of death was slightly
lower than the crude estimation (OR: 1.18, 95%CI: 0.51-2.70);
P = 0.704).
SBP and diastolic blood pressure decreased from
baseline, achieving similar values at study end in both
groups (zofenopril 126.1 ± 16.5/75.4 ± 9.9 mm Hg vs
ramipril 125.6 ± 14.0/75.0 ± 9.0 mm Hg, P = 0.685 and
P = 0.604, respectively). Median NT-proBNP levels (25th
and 95th percentile) were progressively reduced during the
follow-up, although no statistically significant (P = 0.456)
between-treatment differences were observed at study end
(zofenopril 264, 98.5-677.0 pg/mL vs ramipril 189.0, 77.5-
459.8 pg/mL). Improvement in LVEF (increase ≥5%) at the
end of treatment was achieved by 65% of zofenopril- and
65% of ramipril-treated patients (P = 0.862). A deterioration
of renal function was observed during the study in similar
(P = 0.452) proportions in the zofenopril (20%) and ramipril
group (23%).
Concomitant cardiovascular drugs were taken during the
study by 96% of patients receiving zofenopril and 94% receiv-
ing ramipril. The most common concomitant drugs were
lipid-lowering drugs (88% and 90%), followed by β-blockers
(76% of zofenopril-treated and 72% of ramipril-treated
patients), nitrates (55% and 54%), diuretics (44% and 40%),
calcium-channel blockers (13% and 11%), antiarrhythmics
(7% and 8%), ARBs (4% and 3%), cardiac glycosides (3% and
2%), other minor cardiac treatments (28% and 26%).
Safety
Assessment of noncardiovascular adverse events was done
in 768 patients (388 treated with zofenopril and 380 with
ramipril). Overall, 352 (46%) patients reported 784 adverse
events (180 patients and 395 events under zofenopril, 172
patients and 389 events under ramipril). Most of the events
(83%) were of a mild or moderate intensity; 44% of them
(A) (B)
Figure 2. Incidence of the combined primary study end point (cardiovascular [CV] mortality or hospitalization for cardiovascular causes, including
congestive heart failure, acute myocardial infarction, angina or decline in left ventricular ejection fraction >15%) (A) and of hospitalization (B) during the
1-year of treatment with zofenopril plus acetylsalicylic acid (ASA) (continuous lines, n = 365) or ramipril plus ASA (dashed lines, n = 351). Data refer to the
intention-to-treat population. P value from the log-rank statistics.
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were classified as serious. A total of 128 (17%) patients were
withdrawn from the study due to adverse events (66 in the
zofenopril and 62 in the ramipril group).
Events attributed to study treatmentwere 48 and occurred
in 43 patients. The most common drug-related adverse
events were cough, hypotension, asthenia, or vertigo.
Gastrointestinal bleeding or ulcers related to concomitant
treatment with ASA were reported in 6 patients.
No statistically significant differences were observed
between the treatment groups in the distribution of
noncardiovascular adverse events.
Discussion
Our results show that zofenopril has a significantly larger
effect on prevention of 1-year risk of death or hospitalization
than ramipril, although such a superiority is mainly
attributed to a larger decreased rate of cardiovascular
hospitalizations in the zofenopril-treated patients, with no
significant differences in cardiovascular mortality.
Interestingly, the reduction in the risk of major
cardiovascular events in the SMILE-4 study, where ASA
has been added to ACEI treatment, is similar and consistent
with that observed in the previous SMILE trials. In such
studies, including 1956 controls and 1941 zofenopril-treated
patients, the risk reduction of major cardiovascular events
in patients treated early with zofenopril was 29% (30% in the
SMILE-4 study).15,19,20
Regarding ramipril, we can infer data from the AIRE
prospective study,18 in which 2006 patients with clinical
evidence of heart failure at any time after an AMI were
treated with ramipril or placebo, starting on the 2nd to
9th day after the infarction, for an average period of
15 months. Approximately 86% of patients were treated with
5 mg ramipril twice daily at the end of the follow-up. In
this study, mortality from all causes and the rate of major
cardiovascular events were 27% and 19% lower in patients
randomized to receive ramipril, respectively. At the end of
the study, the relative risk of death was 37% lower with
ramipril than placebo in patients receiving ramipril alone
and 22% less in those receiving ramipril plus aspirin at
randomization. Unfortunately, the difference between the
2 study subgroups did not reach statistical significance,
because of the relatively small percentage of patients not
taking aspirin at randomization (22%) and because aspirin
use after randomization was permitted but not taken into
account in the analysis.
So far there has been a controversy on the possible
counteraction of ACEI efficacy by aspirin in patients with
ischemic heart disease or heart failure.2,5 Most of the
studies were retrospective analyses or used hemodynamic
end points, and with the exception of a well-designed
and performed meta-analysis and a pooled analysis of 3
large randomized trials,7,8 none produced results strong
enough to contraindicate the aspirin-ACEI association or
to prove the clinical relevance of this interaction.1,3,6,7,21
Probably, the differences in clinical efficacy among
ACEIs, when combined with ASA, might be related to
differences in their pharmacological features. There is
evidence from small experimental animal studies that
sulfhydryl-containing ACEIs, such as captopril or zofenopril,
maintain their cardiovascular protective effects even in
presence of cyclooxygenase inhibitors,9,12 whereas this
is not the case for enalapril,9 ramipril,10,11 or lisinopril.22
In addition, a direct comparison between zofenopril and
ramipril showed a lower accumulation of bradykinin and
prostaglandins at the lung level in animals treated with
zofenoprilat.23,24 This means that a sulfhydryl ACEI might
have a cardioprotective mechanism of action, which only
in part includes a prostaglandin-mediated mechanism
largely influenced by indomethacin or ASA. An indirect
demonstration of the possible validity of our assumption
may come from the Valsartan in AcuteMyocardial Infarction
(VALIANT) study,19,25 in which the 1-year rate of death from
cardiovascular cause with captopril (25%) was very close to
that observed in our study (29%). In the VALIANT study,
92% of patients were treated with aspirin or other antiplatelet
agents.26
In our study the incidence of adverse events observed
with zofenopril was comparable to that observed with
the reference drug, ramipril, and both drugs showed a
tolerability profile that was largely consistent with previous
clinical observations based on treatment of post-MI with the
same active principles.15,18
We must acknowledge a number of important limitations
of our study. First, the dose of ASA (100 mg once daily)
might have not been sufficient to observe a clear benefit or
to unmask a possible drug-drug interaction with the ACEIs.
However, the available evidence indicates that the lowest
effective and safe daily dose of aspirin for the long-term
prevention of serious vascular events in high-risk patients
is in the range of 75 to 100 mg.16,26 We could not use
a higher dose of ASA, because patients could have been
treated with clopidogrel or ticlopidine following PTCA, and
current evidence and guidelines do not recommend dosages
higher than 100 mg/d in the presence of these drugs.16,17
Second, we cannot exclude that the use of lower or higher
doses of ASA than those selected for our study (eg, 75 mg
or 300 mg) could have led to different results in terms of
outcomes. Third, approximately one-third of the patients
performed a PTCA or received thrombolytic therapy at
entry, but the distribution of such patients was well balanced
between treatments, thus excluding a possible bias. Fourth,
the fact that all patients were treated with zofenopril at entry
might have favored this drug at the expense of ramipril.
However, this was a mandatory ethical choice, because
previous evidence from the SMILE program indicates that
zofenopril has a clear prognostic benefit when used in
the early phase of MI, whereas such an evidence is not
available for ramipril.15,18 Fifth, the combined study end
point was statistically significant, but this was mainly due to
a 35% reduced hospitalization rate in the zofenopril group,
becausemortalitywas not significantly different between the
2 groups, probably because of the relatively short duration
of the observation period. Sixth, some prognostic factors
at baseline were unevenly distributed in the 2 populations,
but a logistic regression analysis adjusted for confounding
factors gave results similar to those obtained by unadjusted
analysis. Seventh, we did not assess platelet function or
specifically address possible pharmacological mechanisms
explaining the interaction between ASA and the ACEIs used
in this study. This was beyond the study aim, and it could
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be the objective of future studies. Finally, it is important to
recognize that our study had no control group with ACE-
inhibitors and no ASA, and equally important no control
group with no active treatment.
Conclusion
The results of the SMILE-4 trial showed that differences
in clinical efficacy may exist when different ACEIs are
combined with ASA. In particular, our study showed a
more favorable impact of zofenopril than ramipril on major
cardiovascular events and in a relatively long-term period of
1 year.
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